Important medical note
This article is a harm-reduction reference. It does not replace medical advice, psychiatric consultation, or appropriate medical follow-up. If you take an antidepressant, do not stop it on your own in order to join a ceremony: abrupt discontinuation can cause withdrawal symptoms, an anxious or depressive relapse, severe insomnia, suicidal thoughts, or psychiatric destabilization.
The right question is therefore not: “how many days should I stop?” The right question is: “do my clinical situation, my exact treatment, my history, and my current level of stability make an ayahuasca retreat appropriate now?” That answer is first assessed by the Connecta Life team; when an orange or red flag appears, it is sent to partner doctors before any participation is confirmed.
Key points in brief
- Ayahuasca contains beta-carbolines that inhibit monoamine oxidase, especially MAO-A, and make DMT orally active. This MAOI action explains a large part of the medication-interaction risk.
- Serotonergic antidepressants such as SSRIs and SNRIs can create a serious risk when combined with an MAOI-like substance: serotonergic overload, autonomic symptoms, confusion, agitation, hyperthermia, and high blood pressure.
- Pharmaceutical MAOIs are a particularly strong contraindication, because they add their own enzymatic inhibition to the MAOI action of ayahuasca.
- Lithium, some tricyclic antidepressants, and several atypical antidepressants require a high level of caution: the mechanisms are not always the same, but psychiatric context and interactions remain sensitive.
- A person taking an antidepressant should never be encouraged to hide their treatment, stop it alone, or choose a retreat that does not require medical screening.
1. Why ayahuasca interacts with antidepressants
Ayahuasca is not simply a plant containing DMT. In its traditional form, it combines a DMT-containing plant with the vine Banisteriopsis caapi, which is rich in harmala alkaloids. These alkaloids temporarily inhibit certain monoamine oxidases. Without that inhibition, orally ingested DMT would be rapidly broken down in the digestive tract and would not have the same psychoactive effect.
This mechanism is exactly what makes ayahuasca powerful, but also what makes it delicate with treatments that act on serotonin, noradrenaline, dopamine, or nervous-system excitability. Antidepressants are not all the same. Some increase available serotonin, some modify several neurotransmitters, some act on receptors, some have a long half-life, and some are prescribed in contexts of depression, anxiety, chronic pain, obsessive-compulsive disorder, bipolar disorder, or sleep disturbance.
In a ceremony, two levels must therefore be assessed at the same time: the medication and the person. The same medication family can be prescribed to two very different people. Someone who has been stable for years on a long-standing treatment is not in the same situation as someone who has just changed dose, is coming out of a severe depressive episode, or is going through an acute anxiety crisis.
2. Antidepressant families that must be declared
In a serious questionnaire, it is not enough to tick “antidepressant: yes/no.” The exact name, dose, duration of use, date of the most recent change, reason for prescription, psychiatric history, and associated treatments must all be declared. Brand names vary by country; the active substances must be identified.
| Family | Common examples | Safety point with ayahuasca |
|---|---|---|
| SSRIs | Fluoxetine, sertraline, paroxetine, escitalopram, citalopram, fluvoxamine | Serotonergic risk with the MAOI effect of ayahuasca; some molecules have a long half-life. |
| SNRIs | Venlafaxine, duloxetine, desvenlafaxine, milnacipran | Serotonergic and noradrenergic risk; pay attention to blood pressure, heart rhythm, and withdrawal. |
| MAOIs | Moclobemide, phenelzine, tranylcypromine, isocarboxazid, selegiline | Major contraindication: adding a pharmaceutical MAOI to the MAOI action of ayahuasca. |
| Tricyclics | Amitriptyline, clomipramine, imipramine, nortriptyline | Possible interactions with serotonin, noradrenaline, the heart, and sedation; the clinical context must be assessed strictly. |
| Atypicals | Mirtazapine, trazodone, bupropion, vortioxetine, agomelatine, mianserin | Variable mechanisms: some affect serotonin, others sleep, anxiety, receptors, or seizure threshold. |
| Associated mood stabilizers | Lithium, lamotrigine, valproate, associated antipsychotics | Often prescribed in more complex clinical pictures; the question becomes psychiatric as much as pharmacological. |
3. The main risk: serotonergic toxicity
Serotonin syndrome appears when there is too much serotonergic stimulation in the body. It is not simply an “emotional intensity.” Signs may include agitation, confusion, diarrhea, nausea, vomiting, fever, tremors, hyperreflexia, abnormal movements, increased heart rate, and rapid changes in blood pressure. Severe forms require urgent medical care.
SSRIs and SNRIs increase serotonin availability. Ayahuasca, through the MAO-A inhibition of its beta-carbolines, can reduce the breakdown of monoamines. Several pharmacology and harm-reduction sources therefore consider the MAOI + SSRI/SNRI association a high-risk situation. The available literature remains limited, but caution is reinforced by reported cases and by the understanding of the mechanism.
The difficulty is that the risk is not always visible from the outside. A person may feel “fine” while an active substance is still present in the body. Fluoxetine, for example, is known for its long half-life; other treatments can also leave pharmacological effects after the last dose. This is why standard timelines copied from the internet are dangerous: they do not account for the medication, dose, age, liver function, interactions, or psychological stability.
4. Other risks that are often underestimated
Abrupt withdrawal
Stopping an antidepressant too quickly can cause difficult symptoms: dizziness, electric-shock sensations, irritability, anxiety, sadness, insomnia, digestive issues, nightmares, fatigue, or a sudden return of the original symptoms. In the context of a retreat, these symptoms may be confused with emotional preparation, even though they signal biological and psychological instability.
Relapse or destabilization
An antidepressant can be the foundation that keeps a person stable. Removing it so they can “do ayahuasca” may sometimes weaken them at the very moment they are about to enter an intense experience. A serious center must be able to say no or suggest postponing, even when the person is highly motivated.
Associated diagnoses
Taking an antidepressant can hide a broader clinical picture: bipolar disorder, past psychotic episodes, complex trauma, suicidal thoughts, eating disorder, addiction, or severe obsessive-compulsive disorder. Ayahuasca can be psychologically confronting. Screening must therefore address the whole history, not only the medication box.
Combined treatments
A person taking an antidepressant may also take an anxiolytic, a sleeping pill, an antipsychotic, a painkiller, a migraine medication, a supplement such as St. John's wort, or a cold product containing dextromethorphan. The accumulation of several products can completely change the assessment.
5. Timelines, half-lives, and false reassurance
The most common temptation is to look for one simple number: 7 days, 14 days, 30 days. That number reassures, but it can be misleading. A safety interval is not calculated only from the last dose. It depends on the half-life of the molecule, its active metabolites, the dose, age, liver function, interactions with other medications, and how the person responds to discontinuation.
Fluoxetine is the classic example of a treatment that can remain pharmacologically relevant long after the last dose. Other antidepressants leave the body faster but may cause more pronounced discontinuation symptoms. SNRIs, in particular, can create difficult discontinuation symptoms in some people. The risk is therefore not only: “is there still medication in the body?” It is also: “what state is the person in after stopping?”
A facilitator who gives a universal timeline takes on a responsibility they cannot carry. A physician can evaluate a tapering or discontinuation schedule if they consider it appropriate. But even a medically supervised discontinuation does not guarantee that the person is ready for a ceremony. Stability after stopping matters as much as stopping itself.
For this reason, a cautious center should avoid statements such as “just stop for two weeks.” A more accurate formulation would be: “some treatments are incompatible while they are active; if discontinuation is being considered, it must be medically supervised beforehand, and the retreat should then be postponed until there has been a sufficient period of stability.”
6. Deciding to postpone: concrete examples
Postponement is not a failure. In ayahuasca work, knowing how to wait can be a form of maturity. These are situations where postponing is generally more reasonable than immediate participation:
- the person has changed antidepressant or dose in the last few weeks;
- they describe a recent worsening of mood, sleep, or anxiety;
- they want to stop their treatment only so they can come, without a coherent medical plan;
- they have recently had suicidal thoughts, hospitalization, a manic episode, or a psychotic episode;
- they take several psychotropic treatments and do not know the exact active substances;
- they refuse to let the center contact or involve their doctor even though the situation is complex;
- they minimize withdrawal symptoms that are already present;
- they are looking for a quick solution to acute suffering.
This last point is essential. An ayahuasca retreat can be deeply meaningful for some people, but it must not become an emergency answer to active depression. When suffering is acute, the first framework to strengthen is medical, psychotherapeutic, family, and social support.
7. What a participant can prepare without changing treatment
When someone discovers that their treatment makes a retreat impossible in the short term, they may feel disappointed or rejected. It is important to offer a preparation pathway that does not go through stopping the medication. Inner work can begin without a ceremony.
For example, they can clarify their intention in writing, strengthen therapeutic follow-up, stabilize sleep, reduce alcohol and recreational drugs, practice gentle breathing or meditation, work on integrating past experiences, read about contraindications, and speak honestly with their doctor about their interest in psychedelic medicines. All of this builds a foundation. Sometimes that foundation shows that the retreat must wait; sometimes it opens, later, a better-framed possibility.
For centers, this posture changes the relationship with the participant. It is not only saying “no.” It is saying: “not now, not under these conditions, and here is what you can clarify in order to take care of yourself.” That nuance makes refusal more human and more responsible.
8. What a serious center should ask
A reference article should be useful for participants, but also for facilitators. For antidepressants, the serious minimum is a written questionnaire followed by an interview. The information to collect is:
- the exact name of each medication, with the active substance if possible;
- daily dose, timing, and start date;
- date of the most recent dose change;
- reason for prescription and known diagnosis;
- history of hospitalization, suicidal crisis, manic episode, psychosis, or bipolar disorder;
- previous discontinuation attempts and withdrawal symptoms;
- other treatments, drugs, alcohol, cannabis, supplements, and over-the-counter products;
- possibility of requesting input from partner doctors if a sensitive signal appears.
The person must also understand that the questionnaire is not administrative. It protects the group, the team, and above all the participant. Lying about a treatment in order to be accepted into a retreat is one of the most dangerous behaviors in this field.
9. How to decide: a three-level logic
Level 1: the medication
Some medications are incompatible or require such caution that the retreat should be postponed. This is particularly true for MAOIs, SSRIs, SNRIs, and certain mixed or associated treatments.
Level 2: clinical stability
Even after medically supervised discontinuation, the question remains: is the person stable without their treatment? For how long? How are they sleeping? Have they regained sufficient balance?
Level 3: the retreat setting
A small-group setting, an experienced facilitator, a preliminary interview, integration, and the ability to refuse a registration reduce risks. They do not replace medical advice.
10. Frequent mistakes
“I will stop just one week before”
This sentence is a warning sign. For some molecules, a few days are not enough. For others, rapid discontinuation is itself more dangerous than participation. The timeline must be medically supervised with full knowledge of the medication and the person.
“My antidepressant is light”
The word “light” does not mean much in pharmacology. A low dose can remain active; a long-standing treatment can modify receptors; a medication prescribed for sleep can act on serotonin or other systems.
“I read that SSRIs only block the effects”
Some studies on classic psychedelics suggest that SSRIs may attenuate certain effects of substances such as LSD or psilocybin. But ayahuasca is specific because it contains MAO inhibitors. Data from one psychedelic molecule cannot simply be transferred to another.
“I don't want to say it, otherwise they will refuse me”
If a center accepts you only because it does not know about your treatment, it is not protecting you. A refusal or postponement can be frustrating, but it is sometimes the most respectful decision.
11. Questions to ask before booking
- Do you ask for the exact name of all medications before confirmation?
- Do you conduct an individual interview, or only a quick form?
- What do you do if someone takes an SSRI, SNRI, MAOI, or lithium?
- Do you plan reinforced safety validation when the treatment is psychiatric?
- Are you willing to refuse or postpone an already paid registration for medical reasons?
- How do you manage someone who arrives in withdrawal, sleepless, or anxious?
- What presence is ensured throughout the entire ceremony night?
- Is there integration after the retreat and follow-up if the experience is difficult?
12. For facilitators: minimum protocol
A prudent protocol does not try to improvise. It formalizes refusal thresholds, postponement cases, and cases that require medical advice. It documents decisions. It also protects the team from commercial or emotional pressure: a person may beg to come, explain that they have already booked their ticket, or say that “everything will be fine.” The facilitator's role is not to give in, but to hold the frame.
A minimum protocol should include:
- a written list of medication families at risk;
- a clear instruction: the center does not ask anyone to stop treatment;
- a message template making clear that no treatment should be stopped alone or under pressure from a retreat;
- a postponement grid for recent treatment changes, recent depressive episode, severe insomnia, or suicidal crisis;
- an emergency procedure and knowledge of the signs of serotonergic toxicity;
- a simple rule: when there is serious doubt, postpone.
13. After the retreat: restarting treatment and integration
The subject does not end the day after the ceremony. If a treatment has been modified within a medical framework, possible restarting, mood monitoring, and integration must be anticipated. Some participants may feel very open, relieved, or convinced that they no longer need anything. That feeling may be sincere, but it must not replace a medical decision.
A responsible team reminds participants that integration is gradual. The person should continue to observe sleep, appetite, emotional stability, relationships, ability to work, and the possible appearance of dark thoughts or unusual symptoms. If a doctor follows the treatment, that doctor must remain the reference for any decision to restart, adjust, or maintain medication.
For facilitators, a clear post-retreat message can prevent a lot of confusion: do not change your treatments alone after a powerful experience; take time to integrate; contact your doctor if your mood becomes unstable; seek help quickly in case of suicidal thoughts, severe insomnia, confusion, or persistent agitation.
14. Quick checklist for a responsible decision
Before confirming a place, participant and center should be able to answer these points clearly. If several answers are unclear, the retreat should wait.
- The exact name of each treatment is known, not only the brand name.
- Any possible treatment adjustment is medically supervised beforehand and is not decided for the retreat.
- The person is not in acute withdrawal, severe insomnia, or a recent psychological crisis.
- The interval since the last dose is consistent with the medication and medically validated.
- Associated treatments have been declared: anxiolytics, sleeping pills, lithium, antipsychotics, opioids, over-the-counter products, supplements.
- The person understands that postponement is not a punishment, but a protective measure.
- The team knows what to do in case of confusion, agitation, unusual physical symptoms, or concern during the ceremony.
This checklist does not replace a medical grid. It helps avoid the most frequent blind spots: minimized treatment, invented timeline, hidden withdrawal, incomplete diagnosis, or last-minute pressure.
15. FAQ
Can you take ayahuasca while on SSRIs?
In a cautious approach, no. SSRIs are generally considered incompatible with ayahuasca while they are active, because of the serotonergic risk linked to the MAOI effect of the vine. Any discontinuation timeline must be decided with a physician, not by a retreat center.
Are SNRIs less risky than SSRIs?
Not necessarily. SNRIs also act on serotonin and add a noradrenergic dimension. Venlafaxine or duloxetine, for example, must be declared and assessed with the same seriousness.
What about mirtazapine, bupropion, or trazodone?
These treatments cannot be reduced to the SSRI category. They have different mechanisms, but may influence receptors, sleep, anxiety, serotonin, or seizure threshold depending on the case. They must therefore be assessed individually.
Is lithium compatible?
Lithium is a very high-caution signal, both for pharmacological reasons and because it is often prescribed in complex bipolar or mood-disorder contexts. An ayahuasca retreat should not be considered without specialized medical advice and strict psychiatric screening.
If my doctor agrees to discontinuation, must the center accept me?
Not automatically. The doctor evaluates the treatment and your health; the center also evaluates the ceremonial setting, the group, the capacity for support, and whether the timing is appropriate. The two forms of caution complement each other.
